MannKind/$MNKD
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Ticker
$MNKD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
405
ISIN
US56400P7069
Website
MannKind Metrics
BasicAdvanced
$1.1B
36.35
$0.10
1.14
-
Price and volume
Market cap
$1.1B
Beta
1.14
52-week high
$7.39
52-week low
$3.63
Average daily volume
2.5M
Financial strength
Current ratio
2.361
Quick ratio
1.881
Long term debt to equity
-178.795
Total debt to equity
-261.717
Interest coverage (TTM)
1.99%
Profitability
EBITDA (TTM)
86.36
Gross margin (TTM)
74.62%
Net profit margin (TTM)
10.12%
Operating margin (TTM)
26.26%
Effective tax rate (TTM)
9.40%
Revenue per employee (TTM)
$730,000
Management effectiveness
Return on assets (TTM)
10.96%
Return on equity (TTM)
-20.87%
Valuation
Price to earnings (TTM)
36.349
Price to revenue (TTM)
3.581
Price to book
-19.55
Price to tangible book (TTM)
-17.42
Price to free cash flow (TTM)
48.853
Free cash flow yield (TTM)
2.05%
Free cash flow per share (TTM)
7.72%
Growth
Revenue change (TTM)
32.50%
Earnings per share change (TTM)
228.27%
3-year revenue growth (CAGR)
62.00%
3-year earnings per share growth (CAGR)
-34.86%
10-year earnings per share growth (CAGR)
-26.50%
What the Analysts think about MannKind
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
Bulls say / Bears say
MannKind's Afrezza® has received approval from India's Central Drugs Standard Control Organisation (CDSCO), opening a significant new market for the company's inhaled insulin product. (globenewswire.com)
The company reported a net income of $7.4 million for Q4 2024, a substantial increase from $1.4 million in the same quarter of the previous year, indicating improved financial performance. (globenewswire.com)
MannKind has expanded its executive leadership team by appointing Dominic Marasco as President of the Endocrine Business Unit, potentially strengthening its strategic direction. (globenewswire.com)
MannKind's total liabilities increased to $472.7 million as of December 31, 2024, up from $721.4 million the previous year, indicating a significant debt burden. (globenewswire.com)
The company's stockholders' deficit stood at $78.8 million at the end of 2024, reflecting ongoing financial challenges. (globenewswire.com)
MannKind's debt-to-equity ratio is -100.8%, indicating that its liabilities exceed its assets, which could pose financial risks. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MannKind Financial Performance
Revenues and expenses
MannKind Earnings Performance
Company profitability
MannKind News
AllArticlesVideos
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
GlobeNewsWire·3 weeks ago
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
GlobeNewsWire·1 month ago
MannKind to Present at Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MannKind stock?
MannKind (MNKD) has a market cap of $1.1B as of June 27, 2025.
What is the P/E ratio for MannKind stock?
The price to earnings (P/E) ratio for MannKind (MNKD) stock is 36.35 as of June 27, 2025.
Does MannKind stock pay dividends?
No, MannKind (MNKD) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next MannKind dividend payment date?
MannKind (MNKD) stock does not pay dividends to its shareholders.
What is the beta indicator for MannKind?
MannKind (MNKD) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.